Upon his return to the United States Presidency, Donald Trump signed a number of executive orders that will not have an immediate impact, but will take effect in the coming weeks.
Trump’s early health moves suggest he aims to dismantle Biden’s drug cost and insurance expansions. What’s next?
President Donald Trump issued a flurry of executive orders and other actions on health care soon after reentering office. Other than signaling he intends to reverse many of Joe Biden’s moves, the orders will have little immediate impact.
The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to negotiate,
The White House told federal agencies to detail by Friday a list of federal employees who are on probationary status and make recommendations on whether they should remain on the job.
President Donald Trump began his second administration with a blitz of policy actions to reorient U.S. government priorities.
Biden spent like no president in history, and, with a sleight of hand, by taking hundreds of billions out of Medicare and spending it on green energy subsidies.
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
President Donald Trump issued a flurry of executive orders and other actions on healthcare, signaling he intends to reverse many of Joe Biden’s moves.